Review article · 2021

Current druggable targets for therapeutic control of Alzheimer's disease

Girdhari Lal Gupta, Nikita Patil Samant

Contemporary Clinical Trials, 109, 106549 · Published 28 August 2021 · DOI 10.1016/j.cct.2021.106549

View at the publisherCite this paper

In brief

“Current druggable targets for therapeutic control of Alzheimer's disease” is a 2021 review article by Girdhari Lal Gupta and Nikita Patil Samant, published in Contemporary Clinical Trials. OpenAlex counts 38 citations as of 15 November 2026, which puts it in the top 5% of works published in 2021 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
38
Most cited in
2024 (14)
Field-weighted impact
0.93
References
117
Authors
2

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Gupta, G. L., & Samant, N. P. (2021). Current druggable targets for therapeutic control of Alzheimer's disease. Contemporary Clinical Trials, 109, 106549. https://doi.org/10.1016/j.cct.2021.106549

MLA 9

Gupta, Girdhari Lal, and Nikita Patil Samant. “Current druggable targets for therapeutic control of Alzheimer's disease.” Contemporary Clinical Trials, vol. 109, 2021, p. 106549. https://doi.org/10.1016/j.cct.2021.106549.

Chicago

Gupta, Girdhari Lal and Nikita Patil Samant. 2021. “Current druggable targets for therapeutic control of Alzheimer's disease.” Contemporary Clinical Trials 109: 106549. https://doi.org/10.1016/j.cct.2021.106549.

Harvard

Gupta, G. L. and Samant, N. P. (2021) ‘Current druggable targets for therapeutic control of Alzheimer's disease’, Contemporary Clinical Trials, 109, p. 106549. doi:10.1016/j.cct.2021.106549.

IEEE

G. L. Gupta and N. P. Samant, “Current druggable targets for therapeutic control of Alzheimer's disease,” Contemporary Clinical Trials, vol. 109, p. 106549, 2021, doi: 10.1016/j.cct.2021.106549.

BibTeX

@article{gupta2021current,
  title     = {{Current druggable targets for therapeutic control of Alzheimer's disease}},
  author    = {Gupta, Girdhari Lal and Samant, Nikita Patil},
  journal   = {Contemporary Clinical Trials},
  year      = {2021},
  volume    = {109},
  pages     = {106549},
  doi       = {10.1016/j.cct.2021.106549},
  url       = {https://doi.org/10.1016/j.cct.2021.106549}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202133
202255
20231010
20241414
202533
202633

Its field-weighted citation impact is 0.93: it has been cited 0.93 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • druggable targets
  • amyloid-beta
  • tau phosphorylation
  • neurotransmitter dysfunction
  • amyloid plaques
  • neurofibrillary tangles
  • symptomatic treatment

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Gupta, G. L., & Samant, N. P. (2021). Current druggable targets for therapeutic control of Alzheimer's disease. Contemporary Clinical Trials, 109, 106549. https://doi.org/10.1016/j.cct.2021.106549

How many times has this paper been cited?

38 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Girdhari Lal Gupta, Nikita Patil Samant.

What is the DOI of this paper?

10.1016/j.cct.2021.106549. The permanent link is https://doi.org/10.1016/j.cct.2021.106549.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.